Sandostatin LAR (octreotide): Reviews and patient testimonials


Medication indications

Sandostatin LAR

Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.

Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome.

Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.

Treatment of TSH-secreting pituitary adenomas:

• when secretion has not normalised after surgery and/or radiotherapy;

• in patients in whom surgery is inappropriate;

• in irradiated patients, until radiotherapy is effective.

Molecule: octreotide

Patients' opinions on Sandostatin LAR

In brief

General satisfaction level: 3.00/10 Learn more

Treatment's effectiveness: 1.00/10 Learn more

Ease of use: 8.00/10 Learn more

Adherence to prescription: 10.00/10 Learn more

Detected side effects: 5.00/10 Learn more

Improvement in the quality of life: 2.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

on 05/10/2021


Your message

Conditions related to this medication

See the fact sheet
Fact sheet


See the fact sheet